智通财经APP获悉，绿叶制药(02186)绩后涨超5%，截至发稿，涨5.39%，报3.52港元，成交额9339.19万 港元。 于中国市场，本集团主要产品均于其四大主要治疗领域(肿瘤科、中枢神经系统、心血管及代谢)具竞争 地位。本集团于中国的主要产品组合包括6款肿瘤治疗领域药品(力扑素、博优诺、百拓维、赞必佳、希 美纳及米美欣)、5款中枢神经系统治疗领域药品(思瑞康、若欣林、瑞可妥、美比瑞及金悠平)、3款心血 管治疗领域药品(血脂康、欧开及麦通纳)及2款代谢治疗领域药品(贝希及博优平)。 就国际市场而言，本集团的产品主要定位于中枢神经系统治疗领域，包括思瑞康、思瑞康缓释片、 Erzofri、Rykindo、利斯的明单日透皮贴剂、利斯的明多日透皮贴剂("利斯的明多天贴 剂"或"LY30410")、罗替高汀贴剂、芬太尼贴剂及丁丙诺啡贴剂。 于报告期内，本集团在肿瘤治疗领域的收入增加13.5%，达12.95亿元。中枢神经系统治疗领域的收入增 加5.4%，达8.68亿元。心血管系统治疗领域的收入减少9.2%，为6.93亿元。代谢治疗领域的收入减少 7.9%，为1.8亿元。 消息面上，8月28日，绿叶制药发布截至202 ...

Core Viewpoint - Green Leaf Pharmaceutical (02186) experienced a stock price increase of over 5% following the release of its interim results for the six months ending June 30, 2025, with a reported revenue of RMB 3.181 billion, reflecting a year-on-year increase of 3.46% [1][2] Financial Performance - The company reported a profit attributable to shareholders of RMB 313 million, a decrease of 19.33% year-on-year [1] - Earnings per share were reported at 8.32 cents [1] Revenue Breakdown by Therapeutic Area - Revenue in the oncology treatment sector increased by 13.5%, reaching RMB 1.295 billion [2] - Revenue in the central nervous system treatment sector grew by 5.4%, totaling RMB 868 million [2] - Revenue in the cardiovascular treatment sector decreased by 9.2%, amounting to RMB 693 million [2] - Revenue in the metabolic treatment sector declined by 7.9%, reaching RMB 180 million [2] Product Portfolio - The company's main products in China include six oncology drugs, five central nervous system drugs, three cardiovascular drugs, and two metabolic drugs [1] - Internationally, the company focuses on central nervous system treatments, offering various formulations and delivery methods [1]

绿叶制药(02186)发布截至2025年6月30日止6个月中期业绩，该集团取得收入人民币31.81亿元(单位下 同)，同比增加3.46%;母公司拥有人应占溢利3.13亿元，同比减少19.33%;每股盈利8.32分。 就国际市场而言，本集团的产品主要定位于中枢神经系统治疗领域，包括思瑞康、思瑞康缓释片、 Erzofri、Rykindo、利斯的明单日透皮贴剂、利斯的明多日透皮贴剂("利斯的明多天贴 剂"或"LY30410")、罗替高汀贴剂、芬太尼贴剂及丁丙诺啡贴剂。 于中国市场，本集团主要产品均于其四大主要治疗领域(肿瘤科、中枢神经系统、心血管及代谢)具竞争 地位。根据IQVIA数据显示，于报告期内，肿瘤科、代谢、中枢神经系统及心血管相关药品分别构成中 国第一、第二、第四及第五大药品市场。本集团于中国的主要产品组合包括6款肿瘤治疗领域药品(力扑 素、博优诺、百拓维、赞必佳、希美纳及米美欣)、5款中枢神经系统治疗领域药品(思瑞康、若欣林、 瑞可妥、美比瑞及金悠平)、3款心血管治疗领域药品(血脂康、欧开及麦通纳)及2款代谢治疗领域药品 (贝希及博优平)。 于报告期内，本集团在肿瘤治疗领域的收入增加13.5%，达12. ...

Core Viewpoint - Green Leaf Pharmaceutical (02186) reported a revenue of 6.061 billion RMB for the fiscal year ending December 31, 2024, reflecting a year-on-year decrease of 1.33% and a net profit attributable to shareholders of 472 million RMB, down 11.4% from the previous year [1][2] Group 1: Financial Performance - The company's revenue for the reporting period was 6.061 billion RMB, a decrease of 1.33% year-on-year [1] - Net profit attributable to shareholders was 472 million RMB, representing a decline of 11.4% year-on-year [1] - Basic earnings per share were reported at 12.54 cents [1] Group 2: Market Position and Product Portfolio - The company holds a competitive position in four major therapeutic areas in the Chinese market: oncology, central nervous system, cardiovascular, and metabolism [1] - According to IQVIA, oncology, metabolism, central nervous system, and cardiovascular drugs accounted for the first, second, fourth, and fifth largest drug markets in China, respectively [1] - The main product portfolio in China includes six oncology drugs, five central nervous system drugs, three cardiovascular drugs, and one metabolism drug [1] Group 3: Sales Performance by Therapeutic Area - Sales in the central nervous system therapeutic area decreased by 4.8%, totaling 1.613 billion RMB [2] - Sales in the oncology therapeutic area decreased by 1.8%, amounting to 2.085 billion RMB [2] - Sales in the cardiovascular therapeutic area decreased by 1.6%, reaching 1.660 billion RMB [2] - Sales in the metabolism therapeutic area saw a decline of 13.7%, totaling 389 million RMB [2] Group 4: Competitive Advantage - The company's 17 major products have established a strong competitive advantage in global high-prevalence disease areas, with market share expected to grow steadily or maintain current levels [2]